Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $16.43 USD
Change Today +0.07 / 0.43%
Volume 1.5K
DSKYF On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (DSKYF) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/17/14 - $18.60
52 Week Low
01/9/15 - $13.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (DSKYF)

Related News

No related news articles were found.

daiichi sankyo co ltd (DSKYF) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (DSKYF) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

32,791 Employees
Last Reported Date: 06/23/14
Founded in 1899

daiichi sankyo co ltd (DSKYF) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥131.0M
Compensation as of Fiscal Year 2014.

daiichi sankyo co ltd (DSKYF) Key Developments

Daiichi Sankyo Company Limited Announces Swissmedic Approves the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland

Daiichi Sankyo Company, Limited announced that Swissmedic has granted approval of Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Simultaneously, Lixiana has received marketing authorization in Switzerland for the treatment of adult patients with venous thromboembolism, including deep vein thrombosis and pulmonary embolism, following previous treatment with fractionated or unfractionated heparin for five days, as well as for the prevention of recurrent VTE. The approved indications in Switzerland for Lixiana are based on data from the phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies, the large and long single comparative global trials of a novel oral anticoagulant in patients with NVAF or acute VTE, involving 21,105 and 8,292 patients, respectively. In the ENGAGE AF-TIMI 48 study, once-daily edoxaban 60 mg demonstrated non-inferiority to warfarin, for the primary efficacy endpoint of occurrence of stroke or SE in patients with NVAF (1.18% vs. 1.50% per year, respectively; hazard ratio, 0.79; 97.5% confidence interval, 0.63 to 0.99, p<0.001). In addition, once-daily edoxaban 60 mg demonstrated a significant 20% risk reduction of major bleeding in patients with NVAF compared to warfarin (2.75% vs. 3.43% per year, respectively; HR, 0.80; 95% CI, 0.71 to 0.91, p<0.001). In the Hokusai-VTE study, once-daily edoxaban 60 mg was non-inferior to warfarin for the primary efficacy endpoint of recurrence of symptomatic VTE (3.2% vs. 3.5% of patients, respectively; HR, 0.89; 95% CI, 0.70 to 1.13, p<0.001). In addition, edoxaban demonstrated a significant 19% risk reduction of clinically relevant bleeding in patients with VTE compared to warfarin (8.5% vs. 10.3% of patients, respectively; HR, 0.81; 95% CI, 0.71 to 0.94, p=0.004). Atrial fibrillation is the most common type of heart rhythm disorder, and is associated with substantial morbidity and mortality. More than 80,000 people in Switzerland suffer from AF, and true prevalence may be higher as up to one third of AF patients do not present with symptoms and go undiagnosed. More than six million Europeans are diagnosed with AF, and this figure is expected to at least double over the next 50 years. One in five of all strokes are as a result of AF. VTE is a major cause of morbidity and mortality. VTE is a major health problem in Europe, with over one million VTE events or deaths per year (France, Germany, Italy, Spain, Sweden, UK), including more than 370,000 VTE-related deaths.

AstraZeneca and Daiichi Sankyo, Inc. Partner to Commercialize OIC Drug in US

AstraZeneca has announced a co-commercialization agreement with Daiichi Sankyo Inc. for MOVANTIK, a once-daily oral peripherally-acting mu-opioid receptor antagonist, or PAMORA, for the treatment of opioid-induced constipation, or OIC, in adults with chronic non-cancer pain, in the US. MOVANTIK was approved by the FDA in September 2014. It was descheduled by the US Drug Enforcement Administration in January 2015 and is no longer labelled as a controlled substance. The launch of MOVANTIK in the US is planned for early April 2015. Under the terms of the agreement, Daiichi Sankyo Inc. will pay a $200 million up-front fee and subsequent sales-related payments of up to $625 million. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo Inc. Both companies will be jointly responsible for commercial activities.

Georgia Department of Community Health Gets $416,000 from Daiichi Sankyo Settlement

Daiichi Sankyo Inc. will pay Georgia about $416,000 as part of a $39 million settlement with the federal government over allegations it gave kickbacks to doctors to get them to prescribe Azor, Benicar, Tribenzor and Welchol. Georgia Attorney General Sam Olens said $162,000 of the settlement will be returned to the Georgia Department of Community Health. The investigation and ensuing settlement stemmed from a false claims action filed by a former Daiichi Sankyo sales representative in 2010. The whistleblower alleged between 2004 and 2011, doctors who participated in or claimed to participate in promotional speaker programs received honoraria payments, lavish meals and other remuneration as kickbacks for prescribing the drugs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKYF:US $16.43 USD +0.07

DSKYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.30 USD -0.31
BioCryst Pharmaceuticals Inc $9.78 USD 0.00
BioMerieux €92.00 EUR -1.05
Infinity Pharmaceuticals Inc $14.86 USD -0.28
Ipsen SA €45.45 EUR +0.75
View Industry Companies

Industry Analysis


Industry Average

Valuation DSKYF Industry Range
Price/Earnings 15.2x
Price/Sales 1.2x
Price/Book 1.3x
Price/Cash Flow 15.3x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at